We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $143M
1-Year Est. Return 102.52%
This Fund
S&P 500
This Quarter Est. Return
+21.15%
1 Year Est. Return
+102.52%
3 Year Est. Return
+167.58%
5 Year Est. Return
+215.85%
10 Year Est. Return
+1,289.38%
AUM
$143M
AUM Growth
+$22.6M
Cap. Flow
+$11.4M
Cap. Flow %
7.98%
Top 10 Hldgs %
39.65%
Holding
91
New
14
Increased
17
Reduced
18
Closed
9

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$3.03M
2
ORKA
Oruka Therapeutics
ORKA
+$2.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$2.67M
4
CBIO
Crescent Biopharma
CBIO
+$2.37M
5
DFTX
Definium Therapeutics
DFTX
+$1.94M

Top Sells

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$13.5M
2
GILD icon
Gilead Sciences
GILD
+$905K
3
RAPP
Rapport Therapeutics
RAPP
+$835K
4
BOLD
Boundless Bio
BOLD
+$746K
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$698K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
1
Contineum Therapeutics
CTNM
$661M
$11.9M 8.32%
727,587
– –
SI
2
Shoulder Innovations Inc
SI
$424M
$8.73M 6.09%
430,407
– –
LLY icon
3
Eli Lilly
LLY
$1.03T
$7.62M 5.32%
6,354
– –
UNH icon
4
UnitedHealth
UNH
$360B
$5.5M 3.84%
13,235
-1,722
-12% -$638K
JNJ icon
5
Johnson & Johnson
JNJ
$671B
$4.63M 3.23%
18,218
– –
ORKA
6
Oruka Therapeutics
ORKA
$6.02B
$4M 2.79%
+41,987
New +$2.8M
BNTX icon
7
BioNTech
BNTX
$25.8B
$3.9M 2.72%
41,869
+19,705
+89% +$1.85M
DFTX
8
Definium Therapeutics
DFTX
$5.11B
$3.68M 2.57%
+78,310
New +$1.94M
DXCM icon
9
DexCom
DXCM
$33.9B
$3.42M 2.39%
50,756
+27,525
+118% +$1.83M
RCUS icon
10
Arcus Biosciences
RCUS
$3.84B
$3.42M 2.39%
110,870
+65,800
+146% +$1.63M
AMGN icon
11
Amgen
AMGN
$240B
$3.34M 2.33%
9,210
– –
SMMT icon
12
Summit Therapeutics
SMMT
$13.7B
$3.21M 2.24%
220,180
+150,565
+216% +$2.67M
IRTC icon
13
iRhythm Holdings
IRTC
$4.07B
$3.1M 2.16%
+26,070
New +$3.03M
ABBV icon
14
AbbVie
ABBV
$460B
$3.07M 2.14%
12,200
– –
MRK icon
15
Merck
MRK
$376B
$2.77M 1.94%
21,480
– –
AVBP icon
16
ArriVent BioPharma
AVBP
$1.53B
$2.75M 1.92%
79,043
+49,030
+163% +$1.45M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$141B
$2.7M 1.88%
5,432
-1,575
-22% -$698K
ARGX icon
18
argenx
ARGX
$65.9B
$2.63M 1.83%
2,831
-733
-21% -$605K
GILD icon
19
Gilead Sciences
GILD
$188B
$2.61M 1.82%
20,620
-6,870
-25% -$905K
INSM icon
20
Insmed
INSM
$27.7B
$2.48M 1.73%
23,216
+3,548
+18% +$430K
TECX
21
Tectonic Therapeutic
TECX
$585M
$2.44M 1.7%
71,009
+51,950
+273% +$1.53M
ISRG icon
22
Intuitive Surgical
ISRG
$131B
$2.33M 1.62%
5,850
+600
+11% +$262K
IMTX icon
23
Immatics
IMTX
$1.44B
$2.28M 1.59%
224,928
+158,098
+237% +$1.67M
SYK icon
24
Stryker
SYK
$118B
$2.25M 1.57%
7,129
+1,255
+21% +$395K
AVTX icon
25
Avalo Therapeutics
AVTX
$1.02B
$2.22M 1.55%
+119,923
New +$1.9M
1
2 3 4

Similar funds

ICMP
Integrated Capital Management (Pennsylvania) Jessup, Pennsylvania $143M AUM 18.2% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
SL
Sonnipe Ltd Douglas, Isle Of Man $143M AUM 76.98% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Sectoral Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sectoral Asset Management held 91 positions worth $143M, up 19% from $121M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management deployed $11.4M of net new capital in Q2 2026, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was iRhythm Holdings: 26,070 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $905K trimmed.

  • Sectoral Asset Management's largest Q2 2026 buy was iRhythm Holdings: 26,070 shares worth $3.1M.
  • Sectoral Asset Management added most to Summit Therapeutics in Q2 2026, an estimated $2.67M increase.
  • Sectoral Asset Management's biggest Q2 2026 reduction was Gilead Sciences, cutting an estimated $905K.
  • Sectoral Asset Management fully exited Evommune Inc in Q2 2026, selling an estimated $13.5M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $143M portfolio in Q2 2026.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2026.
  • Sectoral Asset Management's portfolio value rose 19% quarter-over-quarter to $143M.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.